25, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating symptomatic severe aortic stenosis. This investigational Abbott TAVI system is the first step toward Abbott's software-guided balloon-expandable TAVI system and is designed to build a foundation for artificial intelligence (AI) guided procedures.

2024年2月25日/新闻通讯社/--雅培（纽约证券交易所：ABT）今天宣布了其研究性经导管主动脉瓣植入术（TAVI）球囊扩张系统治疗症状性严重主动脉瓣狭窄的第一例患者手术。这一研究性的雅培TAVI系统是雅培软件引导气球可扩展TAVI系统的第一步，旨在为人工智能（AI）引导程序奠定基础。

Once the investigational balloon-expandable system completes clinical development and is approved by regulatory authorities, Abbott's structural heart portfolio will offer physicians another TAVI management option to meet the patient's needs along with the company's Navitor™ TAVI system, which is already commercially available..

一旦研究性球囊扩张系统完成临床开发并获得监管机构的批准，雅培的结构性心脏投资组合将为医生提供另一种TAVI管理选择，以满足患者的需求，以及该公司已经上市的Navitor™TAVI系统。。

The aortic valve is a heart valve that controls the flow of oxygen-rich blood to the body. With age, calcium may build up in the valve and cause it to narrow – a condition known as aortic stenosis – resulting in the heart needing to work harder to pump blood through the valve. Left untreated, aortic stenosis can cause symptoms, such as chest pain, shortness of breath and fainting, and it can weaken the heart and become life-threatening.

主动脉瓣是控制富氧血液流向身体的心脏瓣膜。随着年龄的增长，钙可能会在瓣膜中积聚并导致瓣膜狭窄，这种情况称为主动脉瓣狭窄，导致心脏需要更加努力地将血液泵入瓣膜。如果不及时治疗，主动脉瓣狭窄会引起胸痛、呼吸急促和晕厥等症状，并且会削弱心脏并危及生命。

Patients who are at risk of open-heart surgery due to age, frailty or having multiple other conditions may benefit from minimally invasive treatment options where a device is delivered to the heart through an artery in the leg. Aortic stenosis remains the most common primary valve disease and its prevalence increases with age, ranging from approximately 2% in adults 70-80 years of age to 9% in adults older than 80 years.1.

由于年龄，体弱或患有多种其他疾病而有心脏直视手术风险的患者可能会受益于微创治疗选择，其中设备通过腿部动脉输送到心脏。主动脉瓣狭窄仍然是最常见的原发性瓣膜病，其患病率随着年龄的增长而增加，从70-80岁成年人的约2%到80岁以上成年人的9%。

The investigational system is a type of balloon-expandable TAVI device, which works by crimping the new heart valve on a deflated balloon. The balloon with the mounted valve is then inserted into the body through an artery in the groin and routed up to the heart. Once properly positioned inside the narrowed heart valve, the balloon is inflated to expand the new valve, taking over the function of the patient's narrow native heart valve.

该研究系统是一种球囊可膨胀TAVI装置，其工作原理是将新的心脏瓣膜压接在放气的球囊上。然后将装有瓣膜的球囊通过腹股沟的动脉插入体内，并到达心脏。一旦正确定位在狭窄的心脏瓣膜内，气球就会充气以扩展新瓣膜，接管患者狭窄的天然心脏瓣膜的功能。

The balloon is then deflated and removed from the body..

然后将气球放气并从身体上取下。。

'Transcatheter aortic valve implantation treatment has benefitted both physicians and patients over the years, but physicians have come to understand one device does not fit all their patients with aortic stenosis,' said Azeem Latib, M.D., section head and director of interventional cardiology and director of structural heart interventions at Montefiore Health System, who conducted the first procedures with the device alongside cardiac surgeon, Vinayak Bapat, M.D., chair of cardiothoracic surgery at the Minneapolis Heart Institute.

“多年来，经导管主动脉瓣植入治疗对医生和患者都有好处，但医生们已经认识到，一种设备并不适合所有主动脉瓣狭窄患者，”蒙特菲奥雷卫生系统介入心脏病学科主任兼结构性心脏干预主任Azeem Latib医学博士说，他与明尼阿波利斯心脏研究所心胸外科主任、心脏外科医生Vinayak Bapat医学博士一起使用该设备进行了第一次手术。

'We, and hospitals worldwide, remain focused on helping this growing patient population by investigating and providing expanded treatment options that adapt to the unique needs and anatomies of patients.'.

“我们和世界各地的医院仍然专注于通过调查和提供适应患者独特需求和解剖结构的扩大治疗选择来帮助不断增长的患者群体。”。

Continued research and expansion of TAVI solutions is necessary for the industry as the needs of physicians and patients evolve. Leveraging insights from physicians, the latest technology advancements and key learnings from the company's TAVI product portfolio, Abbott has developed this differentiated TAVI platform with the objective of building a foundation for the incorporation of AI-guided procedural capabilities.

随着医生和患者需求的发展，TAVI解决方案的持续研究和扩展对于行业来说是必要的。利用医生的见解、最新技术进步和公司TAVI产品组合的关键经验，雅培开发了这种差异化的TAVI平台，目的是为整合AI指导的程序功能奠定基础。

The goal is to enhance ease of use and precision, while offering best-in-class hemodynamic performance, or blood flow through the valve..

目标是提高易用性和精确度，同时提供一流的血液动力学性能或通过瓣膜的血流。。

'Abbott's experience in the TAVI market gives us a unique understanding of the remaining unmet needs, and we're applying this knowledge to develop future therapies to close that gap,' said Sandra Lesenfants, senior vice president of Abbott's structural heart business. 'By closely partnering with physicians on research into new innovations, we're positioned to advance investigational therapies that have the potential to transform patient treatment.' .

雅培结构性心脏业务高级副总裁桑德拉·莱森芬茨（SandraLesenfants）说：“雅培在TAVI市场的经验使我们对尚未满足的需求有了独特的理解，我们正在利用这些知识开发未来的治疗方法，以弥合这一差距。”通过与医生密切合作研究新的创新，我们可以推进有可能改变患者治疗方式的研究疗法。”。

The first-in-human procedures were successfully conducted at the Republican Centre of Emergency Medicine in Tashkent, Uzbekistan, in collaboration with site principal investigator, interventional cardiologist, Saidamir Djafarov, M.D.

与现场首席研究员、介入心脏病专家Saidamir Djafarov医学博士合作，在乌兹别克斯坦塔什干共和国急诊医学中心成功进行了首次人体手术。

About Abbott Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries..

Abbott Abbott是一家全球医疗保健领导者，致力于帮助人们在生命的各个阶段都生活得更加充实。我们的生命改变技术组合涵盖了医疗保健领域，拥有诊断、医疗器械、营养品和品牌仿制药领域的领先业务和产品。我们的114000名同事为160多个国家的人民服务。。